Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

20.50 -0.02 (-0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
What Analysts Are Saying About Schrodinger Stock
Via Benzinga
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
From Schrödinger
Via Business Wire
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Schrödinger Reports Strong Second Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
3 Small-Cap Stocks to Buy at a 52-Week Low
The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
Via InvestorPlace
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
From Schrödinger
Via Business Wire
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond. 
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
The global 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
The 7 AI Categories Were Down 4%, On Average, This Week; Up 1% In May
The 7 AI categories we track dropped, down 4.3% this week, and are now only up 1.3% for the month of May. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger to Present at Jefferies Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
A few enterprising businesses are marketing themselves differently. 
Via The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
The 7 AI Categories Declined, On Average, The First Week Of May
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.